TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34418681

Group type: EXPERIMENTAL
Intervention: Myocardial Infarction (MI)
Number of subjects: 19582

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF) < 35%
Number of subjects: 19582

Group type: EXPERIMENTAL
Intervention: Age > 75 years
Number of subjects: 19582

Group type: EXPERIMENTAL
Intervention: Multivessel coronary artery disease
Number of subjects: 19582

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 19582

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 19582

Group type: EXPERIMENTAL
Intervention: Increased LDL-C
Number of subjects: 19582

Group type: EXPERIMENTAL
Intervention: Increased creatinine levels
Number of subjects: 19582

Group type: EXPERIMENTAL
Intervention: Low haemoglobin
Number of subjects: 19582

Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease
Number of subjects: 19582
Study: 34418951

Group type: EXPERIMENTAL
Intervention: Migraine attack phase
Number of subjects: 15
Study: 34418994

Group type: EXPERIMENTAL
Intervention: Functional avoidance plan (SPECT-guided)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard reference plan (without SPECT imaging data)
Number of subjects: 200
Study: 34419010

Group type: EXPERIMENTAL
Intervention: Collaborative, computer-assisted, psycho-educational intervention (8 sessions delivered by trained therapists, structured telephone calls to monitor progress, usual medical care for chronic diseases)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) including depression treatment according to clinical guidelines and usual medical care for chronic diseases
Number of subjects: 360
Study: 34419046

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 2631

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) in primary prevention subjects (n=557)
Number of subjects: 2631

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) in secondary prevention subjects (n=2074)
Number of subjects: 2631
Study: 34419114

Group type: EXPERIMENTAL
Intervention: Internet-based stress recovery intervention FOREST (6-week program with six modules)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list group (control)
Number of subjects: 0
Study: 34419125

Group type: EXPERIMENTAL
Intervention: Oncogramme® (arm A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current practice without Oncogramme® (arm B)
Number of subjects: 0
Study: 34419134

Group type: EXPERIMENTAL
Intervention: Cycling intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 0
Study: 34419148

Group type: EXPERIMENTAL
Intervention: Photo-supported conversations about well-being (Be Well™) in addition to care as usual
Number of subjects: 70

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 70
Study: 34419393

Group type: EXPERIMENTAL
Intervention: Mitral valve repair
Number of subjects: 104
Study: 34419398

Group type: EXPERIMENTAL
Intervention: Low tube voltage scanning (80 kV)
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: Medium tube voltage scanning (100 kV)
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: High tube voltage scanning (120 kV)
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: Increasing luminal HU (<350, 350-500, and >500 HU)
Number of subjects: 1236
Study: 34419400

Group type: EXPERIMENTAL
Intervention: Stress cardiac magnetic resonance (CMR)
Number of subjects: 755
Study: 34419721

Group type: EXPERIMENTAL
Intervention: 9-step magnetic assisted conversion from sleeve gastrectomy to roux-en-Y gastric bypass (RYGB) and hiatoplasty by single-port.
Number of subjects: 1

Group type: COMPARATOR
Intervention: RYGB
Number of subjects: 1
Study: 34419752

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) for depression; 20 individual sessions over 16 weeks
Number of subjects: 41
Study: 34420124

Group type: EXPERIMENTAL
Intervention: MacuFix® application
Number of subjects: 45

Group type: COMPARATOR
Intervention: Amsler grid
Number of subjects: 45
Study: 34420143

Group type: EXPERIMENTAL
Intervention: Mixed modeling and multiple imputation for handling missing PRO-CTCAE scores
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Including CTCAE grades in the imputation model
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: CTCAE grades as auxiliary variables in multiple imputation
Number of subjects: 171
Study: 34420206

Group type: EXPERIMENTAL
Intervention: Web-based algorithm for seizure classification
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Web-based algorithm
Number of subjects: 262
Study: 34420255

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Expert review
Number of subjects: 256
Study: 34420516

Group type: EXPERIMENTAL
Intervention: Self-reported health status assessed by PROMs at 3 and 12 months after stroke.
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Initial NIHSS score
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Length of inpatient stay
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Diabetes presence
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation presence
Number of subjects: 650
Study: 34420517

Group type: EXPERIMENTAL
Intervention: mild-moderate vomiting (mNVP)
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: severe vomiting (sNVP)
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: severe vomiting with hospitalisation (shNVP)
Number of subjects: 1172

Group type: COMPARATOR
Intervention: no NVP (control group not explicitly mentioned)
Number of subjects: 1172
Study: 34420548

Group type: EXPERIMENTAL
Intervention: 4000 L production-scale alglucosidase alfa
Number of subjects: 67
Study: 34421144

Group type: EXPERIMENTAL
Intervention: Zaleplon for 6 weeks
Number of subjects: 20
Study: 34421148

Group type: EXPERIMENTAL
Intervention: Subanesthetic intravenous ketamine
Number of subjects: 0
Study: 34421298

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR) combined with counselling
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Types of participants identified through thematic analysis
Number of subjects: 18
Study: 34421729

Group type: EXPERIMENTAL
Intervention: Ethical education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical Hatha yoga
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mantra meditation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34421925

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone pulse therapy (IVMP) alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IVMP combined with apheresis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IVMP combined with intravenous immunoglobulin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Other therapies
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Higher levels of T helper cell 2 (Th2)-related cytokines
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Serum NfL levels
Number of subjects: 100
Study: 34422289

Group type: EXPERIMENTAL
Intervention: Multi-modal assessments including head injury assessment (HIA), neuropsychometric assessment (ImPACT), targeted biomarker analysis, and untargeted biomarker analysis.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical assessments (HIA and ImPACT) and blood draws post-injury.
Number of subjects: 0
Study: 34422349

Group type: EXPERIMENTAL
Intervention: Geospatial Test (superior-inferior distance, nodule diameter, radial distance)
Number of subjects: 3630

Group type: COMPARATOR
Intervention: Brock Model
Number of subjects: 3630
Study: 34422854

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34422859

Group type: EXPERIMENTAL
Intervention: Wearable, non-invasive sensor for blood pressure monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34423004

Group type: EXPERIMENTAL
Intervention: CT imaging data used to develop predictive models for lung function post-resection.
Number of subjects: 160
Study: 34423058

Group type: EXPERIMENTAL
Intervention: Transtibial meniscus root repair
Number of subjects: 45
Study: 34423319

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for ARFID (CBT-AR), 20-30 outpatient sessions delivered by therapists.
Number of subjects: 14
Study: 34423355

Group type: EXPERIMENTAL
Intervention: High-sensitive troponin I (TNIH) measured at admission (0 h) and after 1 h
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: High-sensitive troponin I (TNIH) measured at admission (0 h) and after 30 m
Number of subjects: 1003
Study: 34423654

Group type: EXPERIMENTAL
Intervention: 4-item Stroke Scale (4I-SS) ≥4
Number of subjects: 11440

Group type: EXPERIMENTAL
Intervention: 4-item Stroke Scale (4I-SS) ≥7
Number of subjects: 11440

Group type: EXPERIMENTAL
Intervention: 4-item Stroke Scale (4I-SS) score ≥6 including atrial fibrillation
Number of subjects: 11440

Group type: EXPERIMENTAL
Intervention: 4-item Stroke Scale (4I-SS) score ≥7
Number of subjects: 11440
Study: 34424319

Group type: EXPERIMENTAL
Intervention: LCL161 (oral, starting dose, 1500 mg per week)
Number of subjects: 66
Study: 34424505

Group type: EXPERIMENTAL
Intervention: FAPI PET/CT
Number of subjects: 182
Study: 34424546

Group type: COMPARATOR
Intervention: Standard-dose rhGH (approximately 0.3 mg/kg/week)
Number of subjects: 291

Group type: COMPARATOR
Intervention: High-dose rhGH (0.5 mg/kg/week)
Number of subjects: 291

Group type: COMPARATOR
Intervention: rhGH therapy
Number of subjects: 291
Study: 34424934

Group type: EXPERIMENTAL
Intervention: Supplement (2g fish oil with 1500 IU vitamin D3 1x/d + 20-30g whey protein powder with 3g leucine 2x/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isocaloric placebo (corn oil + maltodextrin powder)
Number of subjects: 20
Study: 34425072

Group type: EXPERIMENTAL
Intervention: Awake prone positioning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 34425087

Group type: EXPERIMENTAL
Intervention: Severe lower extremity trauma
Number of subjects: 328
Study: 34425254

Group type: EXPERIMENTAL
Intervention: Salsalate
Number of subjects: 0
Study: 34425261

Group type: EXPERIMENTAL
Intervention: High-dose post-transplantation cyclophosphamide (PTCy)
Number of subjects: 29
Study: 34425406

Group type: EXPERIMENTAL
Intervention: Palbociclib plus endocrine therapy (exemestane or fulvestrant)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 537
Study: 34425763

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (IFNB-1b) treatment started within 6 months before study entry.
Number of subjects: 481
Study: 34425769

Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia (CAC score measured)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 163
Study: 34425815

Group type: EXPERIMENTAL
Intervention: Intensive intervention training for middle managers to promote health in the workplace
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Workplace health promotion programs in progress 12 months after the course
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Workplace RE-AIM scores
Number of subjects: 18
Study: 34425825

Group type: EXPERIMENTAL
Intervention: HIV positive mothers
Number of subjects: 345

Group type: COMPARATOR
Intervention: HIV negative mothers
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: HIV status (both groups)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Self-reported oral health
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Caries experience
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Gingival bleeding
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Children's oral health related quality of life
Number of subjects: 345
Study: 34425850

Group type: EXPERIMENTAL
Intervention: YY-20394 (20-200 mg daily)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: YY-20394 (40 mg q.d.)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: YY-20394 (80 mg q.d.)
Number of subjects: 25
Study: 34425878

Group type: EXPERIMENTAL
Intervention: Resonance frequency breathing (RFB) combined with visual speed of processing (VSOP) cognitive training
Number of subjects: 114

Group type: COMPARATOR
Intervention: Visual speed of processing (VSOP) with guided imagery relaxation (IR) control
Number of subjects: 114

Group type: COMPARATOR
Intervention: IR-only control
Number of subjects: 114
Study: 34425916

Group type: EXPERIMENTAL
Intervention: Restorative yoga
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Circulating microRNAs
Number of subjects: 82
Study: 34425962

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 1392

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1392

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 1392
Study: 34426012

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs)
Number of subjects: 14873

Group type: EXPERIMENTAL
Intervention: Sodium-glucose cotransporter 2 inhibitors (SGLT2is)
Number of subjects: 14873

Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide 1 receptor agonists (GLP-1RAs)
Number of subjects: 14873

Group type: EXPERIMENTAL
Intervention: Steroidal mineralocorticoid receptor antagonists (MRAs)
Number of subjects: 14873
Study: 34426402

Group type: EXPERIMENTAL
Intervention: Subconjunctival dexamethasone implant injected at the end of PK
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Subconjunctival dexamethasone implant
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Steroid eye-drop treatment planned after implant resorption
Number of subjects: 14
Study: 34426443

Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin (Teliso-V) monotherapy at a dose of 1.9 mg/kg once every 2 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin (Teliso-V) monotherapy at a dose of 2.7 mg/kg once every 3 weeks
Number of subjects: 52
Study: 34426550

Group type: EXPERIMENTAL
Intervention: >3.8 mm threshold on CTA
Number of subjects: 100

Group type: COMPARATOR
Intervention: Static appearance of filling defect after 4 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Resolution or decreased length of filling defect
Number of subjects: 100
Study: 34426551

Group type: EXPERIMENTAL
Intervention: NAA metabolite ratios in the motor cortex at baseline
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: MRS NAA metabolite ratios of the motor cortex
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Standardized imaging protocols
Number of subjects: 76
Study: 34426634

Group type: EXPERIMENTAL
Intervention: T2D patients during hypoglycemia
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control subjects during hypoglycemia
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control subjects at 24-h post-hypoglycemia
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: T2D patients at 24-h post-hypoglycemia
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups at 4-h post-hypoglycemia
Number of subjects: 46
Study: 34426940

Group type: EXPERIMENTAL
Intervention: Aducanumab added to standard of care (SOC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 0
Study: 34427465

Group type: EXPERIMENTAL
Intervention: Standard NAC with or without experimental agents
Number of subjects: 0
Study: 34427732

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Essential amino acids (EAA)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: HIIT and EAA combined
Number of subjects: 66
Study: 34427788

Group type: EXPERIMENTAL
Intervention: Medial to lateral (ML) dissection
Number of subjects: 117

Group type: COMPARATOR
Intervention: Lateral to medial (LM) dissection
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: ML group
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: MM/ITC presence
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: MM/ITC positive
Number of subjects: 117
Study: 34427891

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study: 34427990

Group type: EXPERIMENTAL
Intervention: Enasidenib 100 mg daily
Number of subjects: 195

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 195
Study: 34428076

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with gemcitabine and cisplatin plus pembrolizumab
Number of subjects: 39
Study: 34428130

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34428209

Group type: EXPERIMENTAL
Intervention: Advance care planning simulation-based communication training program
Number of subjects: 12
Study: 34428285

Group type: EXPERIMENTAL
Intervention: CC-486 (oral azacitidine) plus R-CHOP
Number of subjects: 52
Study: 34428445

Group type: EXPERIMENTAL
Intervention: Oxaliplatin-based PIPAC
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (non-exposed)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Surface contamination assessment
Number of subjects: 13
Study: 34428922

Group type: EXPERIMENTAL
Intervention: Overactive bladder syndrome (OAB) cases
Number of subjects: 297

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: OAB cases
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Exploratory analyses for OAB cases
Number of subjects: 297
Study: 34428992

Group type: EXPERIMENTAL
Intervention: lenalidomide plus rituximab (R-LEN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: rituximab monotherapy (R-mono)
Number of subjects: 0
Study: 34429088

Group type: EXPERIMENTAL
Intervention: Microbial composition and functional capacity during pregnancy
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Transmission pathways from mother to infant
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Impact of diet on microbial communities
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Microbe-host interactions
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Identification of health-promoting bacteria and potential pathogens
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Biomarkers and mechanisms underlying microbiome profiles
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Development of diet- and microbe-based therapies
Number of subjects: 250
Study: 34429090

Group type: EXPERIMENTAL
Intervention: G-YSQ (German version of the Young Spine Questionnaire)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: KIDSCREEN-10 (assessing health-related quality of life)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: G-YSQ
Number of subjects: 240
Study: 34429131

Group type: EXPERIMENTAL
Intervention: Awake prone position
Number of subjects: 20
Study: 34429332

Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab (tremelimumab 75 mg plus durvalumab 1500 mg once every 28 days for four cycles, then durvalumab alone every 28 days until disease progression)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab
Number of subjects: 58
Study: 34429860

Group type: EXPERIMENTAL
Intervention: Nebulized human adipose-derived MSC-EVs (haMSC-EVs)
Number of subjects: 0
Study: 34430604

Group type: EXPERIMENTAL
Intervention: IV Treprostinil (TRE) at an initial rate of 5 ng/kg/min, increased to 10 ng/kg/min every 30 min until reaching 80 ng/kg/min, administered for 12 hours.
Number of subjects: 8
Study: 34430672

Group type: EXPERIMENTAL
Intervention: Remdesivir (REM)
Number of subjects: 1315

Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy (CPT)
Number of subjects: 1315

Group type: EXPERIMENTAL
Intervention: CPT + REM
Number of subjects: 1315

Group type: COMPARATOR
Intervention: Control group (REM alone)
Number of subjects: 1315
Study: 34430763

Group type: EXPERIMENTAL
Intervention: Prolene sutures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Staple sutures
Number of subjects: 0
Study: 34430790

Group type: EXPERIMENTAL
Intervention: Marzeptacog alfa (activated) (MarzAA) 30 μg/kg SC daily for 50 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Marzeptacog alfa (activated) (MarzAA)
Number of subjects: 11
Study: 34430840

Group type: EXPERIMENTAL
Intervention: IBI362 (LY3305677)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34431322

Group type: EXPERIMENTAL
Intervention: Patients with migraine and TTH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy group of participants
Number of subjects: 0
Study: 34431366

Group type: EXPERIMENTAL
Intervention: CT imaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI imaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PET/CT imaging
Number of subjects: 0
Study: 34431378

Group type: EXPERIMENTAL
Intervention: Deep medullary veins (DMVs) assessment using Susceptibility Weighted Imaging-Phase images.
Number of subjects: 270
Study: 34432142

Group type: EXPERIMENTAL
Intervention: Cystatin C serum levels
Number of subjects: 2035

Group type: EXPERIMENTAL
Intervention: Cystatin C serum levels in males
Number of subjects: 2035

Group type: EXPERIMENTAL
Intervention: Cystatin C serum levels in females
Number of subjects: 2035
Study: 34432155

Group type: EXPERIMENTAL
Intervention: Brachial plexus block (BPB)
Number of subjects: 5340

Group type: EXPERIMENTAL
Intervention: Brachial plexus block (BPB) by supervised trainees
Number of subjects: 5340
Study: 34432206

Group type: EXPERIMENTAL
Intervention: Jianpi Bushen Sequential Formula (JBSF)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo formula
Number of subjects: 400
Study: 34432541

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34432679

Group type: EXPERIMENTAL
Intervention: Combination of INR/(CHE*platelet count)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combination of MELD/(CHE*platelet count)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Baseline MELD score, INR, CHE, and platelet counts
Number of subjects: 33
Study: 34432811

Group type: EXPERIMENTAL
Intervention: Tumor mitotic volume and excessive lesion glycolysis for breast and lung cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surface area of tumors invading beyond the subserosa for colorectal cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical correlates of circulating tumor fraction
Number of subjects: 0